Literature DB >> 6335067

Trimethoprim-sulfamethoxazole pharmacokinetics during continuous ambulatory peritoneal dialysis.

C E Halstenson, R B Blevins, N G Salem, G R Matzke.   

Abstract

Eight adult patients without peritonitis maintained on chronic ambulatory peritoneal dialysis (CAPD) were administered a single oral dose of 320 mg trimethoprim (TMP) and 1600 mg sulfamethoxazole (SMX) to characterize the pharmacokinetics of TMP and SMX. Ten blood samples were drawn following the dose. TMP and SMX-active (SMXA) concentrations were quantified in serum and dialysate. The half-life of TMP and SMXA determined by model independent methods were 33.7 +/- 10.5 h (mean +/- SD) and 13.8 +/- 2.2 h respectively. Total body clearance of TMP was 32.8 +/- 10.1 ml/min and SMXA was 21.9 +/- 6.4 ml/min. CAPD clearance of TMP was 2.27 +/- 0.81 ml/min and SMXA was 1.72 +/- 0.93 ml/min. The average peritoneal dialysate concentrations over the 72-hour collection period of TMP and SMXA were 0.9 +/- 0.1 mg/l and 5.3 +/- 0.8 mg/l respectively. A dose of 320 mg TMP and 1600 mg SMX every 48 hours is recommended for CAPD patients with mild to moderate systemic infections.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6335067

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  6 in total

Review 1.  Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  E Keller; P Reetze; P Schollmeyer
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

2.  Co-trimoxazole (sulphamethoxazole plus trimethoprim) peritoneal barrier transfer pharmacokinetics.

Authors:  J E Svirbely; A J Pesce; S Singh; E J O'Flaherty
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

4.  Pharmacokinetics of cefradine, sulfamethoxazole and trimethoprim and their metabolites in a patient with peritonitis undergoing continuous ambulatory peritoneal dialysis.

Authors:  M Martea; Y A Hekster; T B Vree; A J Voets; J H Berden
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

5.  [Treatment of peritonitis during continuous ambulatory peritoneal dialysis (CAPD) with co-trimoxazole, cefazolin or vancomycin].

Authors:  U König; U Müller; U Binswanger
Journal:  Klin Wochenschr       Date:  1987-07-15

Review 6.  Cotrimoxazole - optimal dosing in the critically ill.

Authors:  Glen R Brown
Journal:  Ann Intensive Care       Date:  2014-04-28       Impact factor: 6.925

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.